Company Profile

Salgomed Inc
Profile last edited on: 9/9/20      CAGE: 5T1Z2      UEI: RKKFJPN1NFP5

Business Identifier: Multidrug mangament platform for complex medication situtions.
Year Founded
2009
First Award
2012
Latest Award
2014
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

14020 Boquita Drive
Del Mar, CA 92014
   (858) 350-6014
   info@salgomed.com
   www.salgomed.com
Location: Single
Congr. District: 49
County: San Diego

Public Profile

Salgomed, Inc. is a biotechnology company - and JLab San Diego alumni - developing solutions to complex medication situations where mulitple drugs are combined. The firmeffectively provides pharmaceutical companies and physicians with actionable information about the clinical efficacy of drug combinations. The firm's multi-disciplinary team has developed and validated novel search algorithms that can discover optimal combinations of these drugs. The firm builds a list of candidate therapies using genomic data, proprietary bioinformatics tools, and input from clinicians Then candidate drugs are tested and their combinations on patient's immune and cancer cells, using an in vitro biomimetic environment providing clinically predictive conditions. Starting from algorithms used in digital communications and in physics, the team has developed a platform that searches for large combined drug interventions, that tests many drug combinations - including immunotherapy drugs - and provides a probability of response to a therapy for each patient.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NSF $225,000
Project Title: Systems approaches to combinatorial therapies targeting cancer metabolism
2013 1 NIH $372,163
Project Title: Search Algorithms for Drug Combinations: Extending Approved Cancer Therapies

Key People / Management

  George Blumberg

  Jacob D Feala

  Andrew McCulloch

  Giovanni Paternostro -- CEO

  Carlo Piermarocchi -- CSO

  Guy Salvesen

Company News

There are no news available.